Literature DB >> 17876003

Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Catherine L Clark1, Klaudia Kosowska-Shick, Lois M Ednie, Peter C Appelbaum.   

Abstract

Testing of 12 pneumococcal strains with differing resistotypes [including tet(M) positive] showed that tigecycline, amoxicillin-clavulanate, imipenem, and ceftriaxone did not select for resistant clones after 50 sequential subcultures. By comparison, azithromycin, clarithromycin, clindamycin, telithromycin, levofloxacin, moxifloxacin, and gemifloxacin did show resistant clones. Tigecycline also yielded a low frequency of resistance in single-step tests compared to all beta-lactams, macrolides/ketolides, and quinolones tested.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17876003      PMCID： PMC2151437          DOI： 10.1128/AAC.00827-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

Authors:  Patricia A Bradford; D Tasha Weaver-Sands; Peter J Petersen
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

5.  Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.

Authors:  Radosław Izdebski; Ewa Sadowy; Janusz Fiett; Paweł Grzesiowski; Marek Gniadkowski; Waleria Hryniewicz
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

6.  Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors:  Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

Authors:  Fionnuala McAleese; Peter Petersen; Alexey Ruzin; Paul M Dunman; Ellen Murphy; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

10.  The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Authors:  Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
Journal:  J Antimicrob Chemother       Date:  2003-07-15       Impact factor: 5.790
View more
  5 in total

1.  In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.

Authors:  Pamela McGhee; Catherine Clark; Klaudia M Kosowska-Shick; Kensuke Nagai; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

2.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

4.  Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis.

Authors:  Hussein Chalhoub; Stefanie Kampmeier; Barbara C Kahl; Françoise Van Bambeke
Journal:  Front Microbiol       Date:  2022-03-28       Impact factor: 5.640

5.  Community-acquired pneumonia caused by carbapenem-resistant Streptococcus pneumoniae: re-examining its prevention and treatment.

Authors:  Asako Doi; Kentaro Iwata; Hiroshi Takegawa; Kanji Miki; Yumi Sono; Hiroaki Nishioka; Jumpei Takeshita; Keisuke Tomii; Tsunekazu Haruta
Journal:  Int J Gen Med       Date:  2014-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.